Results 151 to 160 of about 13,218 (206)
Some of the next articles are maybe not open access.
Pharmacoeconomics of darunavir
Expert Review of Pharmacoeconomics & Outcomes Research, 2011Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008.
Dwight S, Fullerton +3 more
openaire +2 more sources
Darunavir: A comprehensive profile
2021Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV).
Ibrahim A, Darwish +5 more
openaire +2 more sources
Clinical Pharmacokinetics of Darunavir
Clinical Pharmacokinetics, 2007Darunavir (TMC114) is a newly developed HIV-1 protease inhibitor with potent antiviral activity against both wild-type and multidrug resistant HIV-1 strains. The drug is currently approved by the US FDA for antiretroviral treatment-experienced patients with limited therapeutic options.
Michael, Rittweger, Keikawus, Arastéh
openaire +2 more sources
Enfermedades Infecciosas y Microbiología Clínica, 2008
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +1 more source
The resistance profile of darunavir (DRV) was initially explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose of DRV (n=467) with the subsequent addition of data from the placebo arm without etravirine (ETR) of DUET 1 and 2 (n=604).
openaire +1 more source